* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Shanghai Fosun Pharmaceutical (Group) Co EV-to-EBIT Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Competitive Comparison of Shanghai Fosun Pharmaceutical (Group) Co's EV-to-EBIT
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry
Shanghai Fosun Pharmaceutical (Group) Co's current Enterprise Value is $12,590 Mil.
Shanghai Fosun Pharmaceutical (Group) Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $820 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co (OTCPK:SFOSF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Shanghai Fosun Pharmaceutical (Group) Co's Enterprise Value for the quarter that ended in Mar. 2025 was $9,762 Mil.
Shanghai Fosun Pharmaceutical (Group) Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $820 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Shanghai Fosun Pharmaceutical (Group) Co Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
Shanghai Fosun Pharmaceutical (Group) Co Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SFOSF has been successfully added to your 